Conditions & Recovery · Cancer Horizons · February 12, 2024

S6 Ep18: Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews. Also last week, we covered research showing that a lower dose of an anti-emetic drug could have similar efficacy — and fewer side effects — than the standard, higher dose. NCCN Guidelines Give Framework for Childhood Neuroblastoma Tre

Originally published by Cancer Horizons. We curate and add context; they did the reporting.

Related learning